Re: Atezolizumab with Enzalutamide versus Enzalutamide Alone in Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase 3 Trial

T. Powles; K. C. Yuen; S. Gillessen; E. E. Kadel; D. Rathkopf; N. Matsubara; C. G. Drake; K. Fizazi; J. M. Piulats; P. J. Wysocki; G. L. Buchschacher; B. Alekseev; B. Mellado; B. Karaszewska; J. F. Doss; G. Rasuo; A. Datye; S. Mariathasan; P. Williams; C. J. Sweeney

doi:10.1097/JU.0000000000002705

Re: Atezolizumab with Enzalutamide versus Enzalutamide Alone in Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase 3 Trial

T. Powles, K. C. Yuen, S. Gillessen, E. E. Kadel, D. Rathkopf, N. Matsubara, C. G. Drake, K. Fizazi, J. M. Piulats, P. J. Wysocki, G. L. Buchschacher, B. Alekseev, B. Mellado, B. Karaszewska, J. F. Doss, G. Rasuo, A. Datye, S. Mariathasan, P. Williams, C. J. Sweeney

Research output: Contribution to journal › Comment/debate

Original language	English
Pages (from-to)	214-215
Number of pages	2
Journal	Journal of Urology
Volume	208
Issue number	1
DOIs	https://doi.org/10.1097/JU.0000000000002705
Publication status	Published - 1 Jul 2022
Externally published	Yes

Access to Document

10.1097/JU.0000000000002705

Cite this

Powles, T., Yuen, K. C., Gillessen, S., Kadel, E. E., Rathkopf, D., Matsubara, N., Drake, C. G., Fizazi, K., Piulats, J. M., Wysocki, P. J., Buchschacher, G. L., Alekseev, B., Mellado, B., Karaszewska, B., Doss, J. F., Rasuo, G., Datye, A., Mariathasan, S., Williams, P., & Sweeney, C. J. (2022). Re: Atezolizumab with Enzalutamide versus Enzalutamide Alone in Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase 3 Trial. Journal of Urology, 208(1), 214-215. https://doi.org/10.1097/JU.0000000000002705

@article{6db1a23c00ef4acab01d466ebbeb0939,

title = "Re: Atezolizumab with Enzalutamide versus Enzalutamide Alone in Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase 3 Trial",

author = "T. Powles and Yuen, \{K. C.\} and S. Gillessen and Kadel, \{E. E.\} and D. Rathkopf and N. Matsubara and Drake, \{C. G.\} and K. Fizazi and Piulats, \{J. M.\} and Wysocki, \{P. J.\} and Buchschacher, \{G. L.\} and B. Alekseev and B. Mellado and B. Karaszewska and Doss, \{J. F.\} and G. Rasuo and A. Datye and S. Mariathasan and P. Williams and Sweeney, \{C. J.\}",

year = "2022",

month = jul,

day = "1",

doi = "10.1097/JU.0000000000002705",

language = "English",

volume = "208",

pages = "214--215",

journal = "Journal of Urology",

issn = "0022-5347",

number = "1",

}

Powles, T, Yuen, KC, Gillessen, S, Kadel, EE, Rathkopf, D, Matsubara, N, Drake, CG, Fizazi, K, Piulats, JM, Wysocki, PJ, Buchschacher, GL, Alekseev, B, Mellado, B, Karaszewska, B, Doss, JF, Rasuo, G, Datye, A, Mariathasan, S, Williams, P & Sweeney, CJ 2022, 'Re: Atezolizumab with Enzalutamide versus Enzalutamide Alone in Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase 3 Trial', Journal of Urology, vol. 208, no. 1, pp. 214-215. https://doi.org/10.1097/JU.0000000000002705

TY - JOUR

T1 - Re

T2 - Atezolizumab with Enzalutamide versus Enzalutamide Alone in Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase 3 Trial

AU - Powles, T.

AU - Yuen, K. C.

AU - Gillessen, S.

AU - Kadel, E. E.

AU - Rathkopf, D.

AU - Matsubara, N.

AU - Drake, C. G.

AU - Fizazi, K.

AU - Piulats, J. M.

AU - Wysocki, P. J.

AU - Buchschacher, G. L.

AU - Alekseev, B.

AU - Mellado, B.

AU - Karaszewska, B.

AU - Doss, J. F.

AU - Rasuo, G.

AU - Datye, A.

AU - Mariathasan, S.

AU - Williams, P.

AU - Sweeney, C. J.

PY - 2022/7/1

Y1 - 2022/7/1

UR - http://www.scopus.com/inward/record.url?scp=85132996904&partnerID=8YFLogxK

U2 - 10.1097/JU.0000000000002705

DO - 10.1097/JU.0000000000002705

M3 - Comment/debate

C2 - 35467383

AN - SCOPUS:85132996904

SN - 0022-5347

VL - 208

SP - 214

EP - 215

JO - Journal of Urology

JF - Journal of Urology

IS - 1

ER -

Re: Atezolizumab with Enzalutamide versus Enzalutamide Alone in Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase 3 Trial

Access to Document

Other files and links

Cite this